NCT00538187 2015-12-04Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1 Terminated18 enrolled
NCT00933985 2014-05-01Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaNational Cancer Institute (NCI)Phase 1 Terminated22 enrolled